What T3 Pharmaceuticals does

T3 Pharmaceuticals AG is a clinical-stage Swiss biotechnology company founded in May 2015 and based in Allschwil (Basel), Switzerland. The company has developed a proprietary bacterial delivery platform based on an engineered, attenuated strain of Yersinia enterocolitica that exploits the bacterium's natural Type III Secretion (T3S) system to deliver therapeutic proteins directly into solid tumor cells. By selectively colonizing tumor tissue and injecting immune-modulating payloads (e.g., cytokines, antibodies, T-cell engagers) into the tumor microenvironment, the platform aims to convert immunologically cold tumors into hot, inflamed ones that respond to systemic therapy.

The company's lead clinical candidate, T3P-Y058-739, entered a first-in-human Phase I dose-escalation trial in patients with advanced solid tumors and is designed to deliver a therapeutic protein payload via the T3S mechanism. The company operated as a venture-backed R&D organization, raising approximately CHF 40 million across three financing rounds between 2016 and 2020 from investors including BIVF, Reference Capital SA, and Wille Finance AG, supplemented by non-dilutive grants from Gebert Rüf Stiftung and the Innosuisse Swiss Accelerator program. Scientific founders are affiliated with the University of Basel Biozentrum, and the Scientific Advisory Board includes researchers with direct expertise in the T3S system.

T3 Pharmaceuticals was acquired by Boehringer Ingelheim in November 2023 in a transaction valued at up to CHF 450 million (upfront plus milestone payments), integrating the platform into BI's immuno-oncology R&D portfolio. As a pre-revenue clinical-stage biotech, the company had no commercial product, no product pricing model, and no go-to-market channel at the time of acquisition. The business model was venture-funded R&D progression toward either an out-licensing event, partnership, or trade sale, with the BI acquisition representing the realized exit pathway. Post-acquisition, the company operates as a BI subsidiary with the platform now funded through corporate R&D budgets rather than external capital markets.

Name

T3 Pharmaceuticals

Legal name

T3 Pharmaceuticals AG

Website

https://t3pharma.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

11–50 employees

Short description

T3 Pharmaceuticals AG is a clinical-stage Swiss biotech developing engineered Yersinia enterocolitica-based bacterial therapies that deliver immune-modulating proteins into solid tumors via the Type III Secretion system. The company was acquired by Boehringer Ingelheim in November 2023.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Bacterial cancer therapy
• Immuno-oncology therapeutics
• Live biotherapeutic products
• Tumor-targeted protein delivery
• Solid tumor treatment

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Acquisition proceeds (up to CHF 450 million): Privately-held company acquired by Boehringer Ingelheim in November 2023 for up to CHF 450 million; pre-acquisition revenue derived from non-dilutive grants and milestone-based R&D collaboration rather than commercial product sales.
2. Non-dilutive grants and accelerator funding: Pre-commercial revenue derived from grants including Innosuisse Swiss Accelerator (CHF 2.5 million, 2023), Gebert Rüf Stiftung (CHF 400,000 over two years, 2017), BaseLaunch accelerator funding, CTI/KTI, and the W.A. de Vigier Foundation prize (CHF 100,000, 2019).
3. Venture / private equity financing rounds: Capital raised through multiple venture rounds: first financing round (2016, private Swiss investors), second round >CHF 12M (2019), third round >CHF 25M (2020, total cumulative CHF 40M).

Go-to-market motion1 record

Core offering

T3 Pharmaceuticals develops a proprietary live-bacterial immuno-oncology platform that uses engineered Yersinia enterocolitica bacteria to selectively colonize solid tumors and act as nano-syringes via the bacterial type III secretion (T3S) system to deliver chosen immune-modulating proteins into tumor cells. The company's lead candidate, T3P-Y058-739, is the first therapeutic product from this platform and was in a Phase I clinical trial for solid tumors at the time of the company's acquisition by Boehringer Ingelheim.

Product overview

T3 Pharmaceuticals AG offers a single proprietary technology platform (the T3S Protein Delivery Platform) built on the bacterial type III secretion system, from which it has developed a focused pipeline of bacteria-based immuno-oncology therapies for solid tumors. Its sole named clinical-stage product is the lead asset T3P-Y058-739, which is the first therapeutic candidate generated by the platform and was undergoing a Phase I clinical trial at the time of the company's acquisition by Boehringer Ingelheim in November 2023. The platform and lead program are tightly integrated: the platform provides the engineered Yersinia enterocolitica bacterial vehicle and intracellular protein-delivery mechanism, while T3P-Y058-739 represents the first product instantiation designed to induce a tumor-selective immune response within solid tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• T3P-Y058-739 T3 Pharma's lead immuno-oncology therapeutic candidate, designed to induce a highly specific immune response selectively within solid tumors. It is the first therapeutic candidate built on T3 Pharma's proprietary type III secretion (T3S) protein delivery platform using engineered Yersinia enterocolitica bacteria, and was being tested in a Phase I clinical trial in solid tumors at the time of the company's acquisition by Boehringer Ingelheim.
• T3S Protein Delivery Platform Proprietary cancer therapy platform built by repurposing the bacterial type III secretion (T3S) system. Genetically engineered Yersinia enterocolitica bacteria selectively colonize solid tumors (via removal of key virulence factors) and act as nano-syringe delivery vehicles, injecting chosen bioactive proteins into tumor cells to trigger immune responses such as immune cell activation or cell death. The platform is versatile and can be loaded with multiple immune-modulatory proteins to enable immuno-oncology combination therapies in a single agent.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• BioMed Valley Discoveries: Clinical-stage biotech developing Clostridium novyi-NT spores that selectively colonize hypoxic regions of solid tumors — the closest mechanistic analog to T3 Pharma's tumor-selective live-bacterial cancer therapy platform. Both target solid tumors using engineered bacteria with intrinsic tumor tropism.
• AntiCancer Inc: Pioneer of bacteria-based cancer therapy approaches (notably Salmonella typhimurium and obligate anaerobes) for solid tumors. Pioneered by Dr. Zheng Cui, AntiCancer Inc is one of the few commercial-stage entities pursuing bacteria-mediated tumor killing, directly comparable to T3 Pharma's modality.

Emerging players

• Lytix Biopharma: Clinical-stage Norwegian biotech developing oncolytic antimicrobial peptides for solid tumors — same philosophy of using biological agents to selectively disrupt tumor cells and stimulate immune response, though mechanistically distinct from T3's bacterial delivery approach.
• Genelux Corporation: Clinical-stage biotech developing engineered oncolytic vaccinia viruses (e.g., GL-ONC1) that selectively replicate in and lyse solid tumor cells — a comparable 'biological vehicle for tumor-selective payload delivery' strategy that competes with T3 Pharma in the immuno-oncology niche.
• Akamis Bio: Formerly PsiOxus Therapeutics; clinical-stage company developing engineered oncolytic adenoviruses (NG-348, NG-641) that deliver immune-modulating payloads into solid tumors — directly comparable to T3 Pharma's T3S platform in concept, differing only in viral vs. bacterial delivery vehicle.
• Nouscom: Clinical-stage European biotech developing viral cancer immunotherapies and off-the-shelf neoantigen vaccines for solid tumors. Comparable to T3 Pharma as a Basel-adjacent European clinical-stage immuno-oncology player using engineered biological vehicles for tumor-selective payload delivery.
• Turnstone Biologics: Clinical-stage biotech developing oncolytic viral immunotherapies and tumor-infiltrating lymphocyte (TIL) therapies for solid tumors — overlapping with T3 Pharma's immuno-oncology focus on solid tumors using biologically engineered payloads.
• Istari Oncology: Clinical-stage biotech developing PVSRIPO, a polio-rhinovirus chimera, for solid tumors including glioblastoma and melanoma — comparable to T3 Pharma as a tumor-selective biological immunotherapeutic modality targeting solid tumors.
• VBL Therapeutics: Clinical-stage biotech developing VB-111 (ofranergene obadenovec), an oncolytic virus-based gene therapy for solid tumors. Comparable to T3 Pharma as a late-stage clinical immuno-oncology asset using engineered biological vectors to deliver anti-cancer payloads.

Broad incumbents

• Boehringer Ingelheim: Now the parent company of T3 Pharma, Boehringer Ingelheim operates a broad immuno-oncology portfolio spanning T-cell engagers, oncolytic viruses, and cancer vaccines. Relevant as the broad incumbent integrating T3's bacterial delivery platform into a wider I-O franchise.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/t3-pharmaceuticals-gmbh
• Xx.com/PharmaT3

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T3 Pharmaceuticals